Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Merck
Express Scripts
AstraZeneca
McKinsey

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR CISATRACURIUM BESYLATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cisatracurium Besylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02508857 ↗ Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries Completed Instituto do Cancer do Estado de São Paulo Phase 4 2010-01-01 Magnesium sulfate has been reported to improve postoperative pain, but evidence is still controversial. Some studies demonstrated benefits while others concluded that there is no efficacy. Aim: the aim of the study was to compare the effect of intravenous infusion of magnesium sulfate to ketorolac during laparoscopic gynecologic oncology surgeries. Methods: We designed a double-blind randomized controlled trial that compared intravenous magnesium sulfate to ketorolac and saline solution in postoperative pain, morphine consumption and opioid related side effects.
NCT02509078 ↗ Reevaluation Of Systemic Early Neuromuscular Blockade Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2016-01-04 This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged.
NCT02509078 ↗ Reevaluation Of Systemic Early Neuromuscular Blockade Completed Massachusetts General Hospital Phase 3 2016-01-04 This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged.
NCT02588118 ↗ Gender and PK-PD of Propofol and Cisatracurium Completed Medical University of Graz 2010-01-01 In recent years it has become clear that gender differences exist both in the pharmacokinetics and the pharmacodynamics of drugs related to the practice of anesthesia. Differences in pharmacokinetics are more straightforward to study than differences in clinical effects. However, isolated pharmacokinetic data are of less value if they are not accompanied by measurements of clinical effects. Males are more sensitive than females to propofol. It may therefore be necessary to decrease the propofol dose by 30-40% in males. Females have 20-30% greater sensitivity to the muscle relaxant effects.
NCT02820025 ↗ The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence Unknown status General Hospital of Ningxia Medical University N/A 2015-10-01 The current study is designed to investigate the difference of plasma orexin A levels between doxapram group and controlled group at emergence time from sevoflurane-remifentanil anesthesia who will undergo elective lumbar surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cisatracurium Besylate

Condition Name

Condition Name for Cisatracurium Besylate
Intervention Trials
Anesthesia 2
Neuromuscular Blockade 1
Pain, Postoperative 1
Paralysis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cisatracurium Besylate
Intervention Trials
Respiratory Distress Syndrome, Newborn 2
Respiratory Distress Syndrome, Adult 2
Respiratory Distress Syndrome 2
Acute Lung Injury 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cisatracurium Besylate

Trials by Country

Trials by Country for Cisatracurium Besylate
Location Trials
United States 17
China 3
Brazil 1
Austria 1
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cisatracurium Besylate
Location Trials
Washington 1
Mississippi 1
Colorado 1
Indiana 1
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cisatracurium Besylate

Clinical Trial Phase

Clinical Trial Phase for Cisatracurium Besylate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
N/A 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cisatracurium Besylate
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cisatracurium Besylate

Sponsor Name

Sponsor Name for Cisatracurium Besylate
Sponsor Trials
General Hospital of Ningxia Medical University 2
Medical University of Graz 1
Mahidol University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cisatracurium Besylate
Sponsor Trials
Other 8
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Boehringer Ingelheim
Express Scripts
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.